Category: News

mtsc oxford university
We have added a further event to our forthcoming conference schedule for the month of December.

We will now also be in attendance at the following event:

Event: The Future of Drug Discovery: Open Innovation
Date: 4 December, 2014
Venue: Medical Sciences Teaching Centre, University of Oxford

Should you wish to meet our representative at this event, please email:

r.wilkes@charnwood-molecular.com

conference1
In December, Charnwood representatives will be attending the following conferences.

Event: Recent Disclosures of Clinical Candidates
Date: 4 December, 2014
Venue: NHLI, Kensington, London

Event: 2nd Winter Process Chemistry Conference
Date: December 10-12, 2014
Venue: Manchester Conference Centre, Manchester, UK

Our representatives will be in attendance and available to meet any interested attendees or exhibitors.

Should you wish to organise a meeting in advance of the event, please email:

email: info@charnwood-molecular.com

We look forward to seeing you there!

lab1

Charnwood Molecular are recruiting……

As part of an ongoing expansion to meet the rising demand for our services, we are looking to recruit a number of experienced synthetic and medicinal chemists to join our project teams.

For further information and to apply for a post, please click here:

http://jobs.rsc.org/job/7325/synthetic-and-medicinal-chemists/

Medchem2014
Charnwood are in attendance at Medchem 2014, a one day conference on medicinal chemistry, which takes place on Friday, 21st November in Braine l’Alleud, Belgium.

The venue is the “Lloyd Conference” room at UCB Pharma in Braine-l’Alleud.

We would welcome the opportunity to meet with any interested parties who are in attendance at the event.

Please do not hesitate to get in touch, should you be going to the event and wish to discuss anything with Charnwood’s representatives.

Please email:

Dr Sylvain Blanc – email: s.blanc@charnwood-molecular.com

We look forward to seeing you there!

conference1Charnwood Molecular is venturing into the Brazilian market for the first time….

The 7th Brazilian Symposium on Medicinal Chemistry (BrazMedChem2014) will be held at the Campos do Jordao Convention Center, in Campos do Jordao (Sao Paulo State) Brazil, from November 9 to 12, 2014.

The event will allow international scientists will get together in Campos do Jordao to discuss the intricacies of the drug discovery process.

Our representatives will be in attendance and available to meet any interested parties from companies looking at outsourced chemistry services.

Should you wish to organise a short meeting in advance of the event, please email:

Dr Sylvain Blanc – email: s.blanc@charnwood-molecular.com

We look forward to seeing you there!

charnwood updated conferences
Charnwood has added to its forthcoming conference schedule, and in the near future it will be in attendance at the following events, conferences and exhibitions.

If you would like further information on our participation in any of these, or would like to arrange to meet one of our representatives at any of the venues, please contact us via email at:
info@charnwood-molecular.com

Event: 7th Brazilian Symposium on Medicinal Chemistry (BrazMedChem2014)
Date: November 9th to 12th 2014
Venue: Campos do Jordao (Sao Paulo State), Brazil

Event: New Vistas in GPCR Research: the Dawn of an Exciting Drug Discovery Era?
Date: November 21st 2014
Venue: Braine-L’Alleud, Belgium

Event: CNS Drug Discovery
Date: November 26th 2014
Venue: Takeda, Cambridge, UK

twitter banner

Charnwood Molecular are now on twitter. Follow us to keep up to date with all the latest happenings.

You can view our profile here:

Charnwood Molecular on Twitter

We look forward to you following us!

London11Charnwood Molecular is sponsoring a forthcoming scientific conference which promises to highlight the success of successful outsourcing to the biotechnology/pharmaceutical industry.

The outsourcing sector increasingly supports the pharmaceutical industry and the relationship between the two has developed enormously over the last 20 years – a development which Charnwood has embraced and built upon. With a sharp rise in outsourcing providers in the drug discovery sector, Charnwood has developed business in the area and continues to do so.

The event takes place on the 30th September 2014 at the Society of Chemical Industry in London, United Kingdom. The conference seeks to illustrate these developments along with current challenges and best practice as seen from the suppliers view point.

Speakers include those working in CROs from drug discovery through to development and will highlight what makes a successful collaboration, together with some potential pitfalls.

More details on the event are available here:

The Secrets of Success: CRO views of successful outsourcing

European Life Science Awards photo - CharnwoodCharnwood Molecular has been recognised for its unique collaborative venture with French company, Hybrigenics.

Working in conjunction with Hybrigenics Services, Charnwood’s expertise in chemical research contributed to the development of a yeast-chemical hybrid screening system, known as ULTImate YChemH. The system has now received the “Most Innovative New Service” of the year award, by the European Life Science Awards, presented to Hybrigenics Services, during the 4th Annual European Lab Automation Exhibition in Barcelona.

Charnwood Molecular’s involvement in the partnership sees the company using its expertise to link bio-active molecules for further analysis by Paris-based Hybrigenics Services,, using their yeast molecular biology machinery. The venture was the result of a two year long commercial trialling phase, which was supported by European funding.

The project is the result of a joint development venture amounting to a total investment of nearly one million Euros, which has been supported up to 40% of the costs by a European Union subsidy under the Eurostars® programme.

Using a chemical linkage adaptation of its optimized “Yeast Two-Hybrid” technology, renamed “yeast chemical-hybrid” (ULTImate YChemH), Hybrigenics Services screens the molecule provided by Charnwood Molecular as a “bait” against its cDNA or genomic libraries expressing millions of “prey” protein fragments to identify target proteins with which this tested molecule interacts.
These exhaustive screenings can be of interest from both safety and efficiency angles. It is hoped that the technology may uncover a full range of related targets, accounting for the whole spectrum of therapeutic activities of a drug (so-called “on-targets”) and/or explain unexpected side effects exerted through unsuspected targets (so-called “off-targets”). Some drugs are active in whole cellular or animal models, but their active mechanisms remain unknown: the ULTImate YChemH technology may find a relevant target for these “orphan” drugs, in a process called “drug de-orphanisation” It may also be relevant for widely used chemicals in every day products to ascertain that they do not interact with any protein.

“This Life Science Award is a great recognition of the breakthrough that the yeast-chemical hybrid system represents,” stated Dr Sylvain Blanc, Business Development Manager of Charnwood Molecular. “Now, just one year after launch, we are working hard to transform this technical achievement into a commercial success for both ourselves and Hybrigenics Services,” he added.

Charnwood involved in collaborative approach to new business

Charnwood Molecular has been featured in the RSC’s Chemistry World publication, for its innovative approach in new business development through collaborative working.

The full Chemistry World article is viewable here:
“Co-operation keeps contracts coming”

Charnwood works with other leading companies who are based at BioCity and actively encourages co-operation between companies in the facility.

This enables Charnwood to offer an “in-house” seamless, integrated discovery and development service by using the available resources within one facility and use the expertise of several other companies to provide this “single service solution”.

The grouping consists of separate entities with unparalleled expertise in a range of drug discovery fields, providing a fully integrated drug discovery capability.